StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

TARSBullishAnalyst Target Updateanalyst
Medium materiality6/10

Tarsus Pharmaceuticals resumed with a Buy at Goldman Sachs

Sep 24, 2026, 6:33 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Upside potential from analyst upgrade.

AI summary

What happened, with direct paths to the underlying reporting

Goldman Sachs initiates Buy with a target of $116; current price around $74.29.

  • Goldman Sachs: Buy target 116; price 74.29

Key facts

  1. 01

    Target: $116

  2. 02

    Posted price: $74.29

  3. 03

    Analyst firm: Goldman Sachs

  4. 04

    Analyst: Andrea Newkirk

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.